AstraZeneca Still Waiting For FDA Decision To Resume U.S. Trial

The U.S. trial of AstraZeneca’s COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed.

U.S. Health and Human Services Secretary Alex Azar said on Wednesday the continued suspension showed the FDA took vaccine safety seriously.

A document posted online by Oxford university last week stated the illness in a British participant that triggered the pause on Sept. 6 may not have been associated with the vaccine.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor